Global Hereditary Genetic Testing Market| BIS Research

A quick peek into the report

Report Description

Market Report Coverage - Hereditary Genetic Testing
Forecast Period: 2020-2030
Value Estimation by 2030: $67.39 Bill

Market Report Coverage - Hereditary Genetic Testing
Base Year	2019	Market Size in 2019	$16.66 Billion
Forecast Period	2020-2030	Value Projection and Estimation by 2030	$67.39 Billion
CAGR During Forecast Period	13.59%	Number of Tables	18
Number of Pages	236	Number of Figures	150
Research Hours
Market Segmentation	• Product Type:Kits, Consumables, and Services • Sample Type: Tumor Tissue, Blood, Saliva, Bone Marrow • Technology: Next Generation Sequencing, Polymerase Chain Reaction,Immunohistochemistry, In-situ Hybridization, Microarray Techniques • Oncology Genetic Testing:Breast,Colorectal,Prostate, Lung, Melanoma • Cardiology Genetic Testing:Cardiomyopathy,Aortopathy, Arrythmia • Neurology Genetic Testing:Epilepsy, Neurodegenerative Disorders, Neuromuscular Disorders • Other Genetic Testing: Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing • Application Area: Academia and Research Centers, Clinical Diagnostics, Drug Discovery, Monitoring and Screening
Regional Segmentation	• North America – U.S., Canada • Europe – Germany, France, Italy, U.K., Spain, Russia, Netherlands • Asia-Pacific – Japan, China, India, Australia, Singapore • Latin America – Brazil, Mexico • Rest-of-the-World – Kingdom of Saudi Arabia (K.S.A.), U.A.E., Palestine, Algeria
Cross Segmentation	• North America – Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing • Europe – Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing • Asia-Pacific - Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing • Latin America – Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing • Rest-of-the-World – Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing
Growth Drivers	• Rising Prevalence of Genetic Disorders • Increasing Prevalence of Various Types of Cancer, Globally • Increasing Research Funding in the Field of Genomics
Market Challenges	• Expensive Sequencing Procedures and Their Applications in Medical Treatments • High Capital Requirement Hampering the Expansion of Global Reach • Stringent Regulatory Standards
Market Opportunities	• Technological Advancements for Exome Sequencing • Rise of Direct-to-Consumer (DTC) Testing Services • Massive Scope for Adoption of NGS-Based in Emerging Nations
Key Companies Profiled	Agilent Technologies, Inc., Ambry Genetics, Beijing Genomics Institute (BGI), CENTOGENE AG, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Inc. Illumina, Inc. , Laboratory Corporation of America Holdings, Myriad Genetics, Inc., PerkinElmer, Inc., Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc.

Key Questions Answered in this Report:

What are the major market drivers, challenges, and opportunities in the hereditary genetic testing?

Market Overview

The global market for hereditary genetic testing is predicted to grow at a CAGR of 13.59% over the forecast period of 2020-2030.

The hereditary genetic testinghas grown significantly since the technology was first commercialized, but it is important to quantify that growth and describe future trends. The genome testing industry is proliferating, and its growth is expected to continue at its torrid pace. However, there are significant challenges that may dampen future growth if not addressed.

Our healthcare experts have found hereditary genetic testing to be one of the most rapidly evolving technologies, and the global market for hereditary genetic testing is predicted to grow at a CAGR of 13.59% over the forecast period of 2020-2030.

The unmet clinical needs for better tools to predict, diagnose, treat, and monitor disease are acting as significant factors driving the growth of sequencing industry. Other factors driving the growth include the increased understanding of the molecular basis of disease, patient demand, industry investment, and regulations that allow marketing of tests without FDA approval.

Despite rapid advanced sequencing industry growth, there are several key issues that are needed to be addressed to facilitate future growth. The relatively high total costs of delivering sequencing test results compared with other technology platforms, and limited coverage by payers, are the key challenges to the growth of this industry. Whole genome and exome sequencing remain relatively costly requiring initial equipment investment, specialized workforce requirements, and time-intensive variant interpretation.

Within the research report, the market is segmented on the basis of oncology genetic testing, cardiology genetic testing, neurology genetic testing, product, sample, application area, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the application of next generation sequencing on the global level has created a buzz among companies to invest in the products and services of whole genome and exome sequencing. Due to the diverse product portfolio and intense market penetration, whole genome and exome has been a pioneer in this field and been a significant competitor in this market.

On the basis of region, North America holds the largest share, due to improved healthcare infrastructure, rise in per capita income, and improvisedreimbursement policies in the region. Apart from this, Latin America and the Asia-Pacific region are anticipated to grow at the fastest CAGR during the forecast period.

Download this TOC

Request a Sample

1.1 Hereditary Genetic Testing
1.2 Inclusion and Exclusion

2.1 Scope of the Study
2.2 Key Questions Answered in the Report

3.1   Primary Data Sources
3.2   Secondary Data Sources
3.3   Market Estimation Model
3.4   Criteria for Company Profiling

4.1   Mergers and Acquisitions
4.2   Product Launches
4.3   Synergistic Activities
4.4   Business Expansion Activities and Others
4.5   Market Share Analysis
4.6   Growth Share Analysis

5.1 Current State of Hereditary Genetic Testing
5.2 Market Footprint and Future Potential

6.1   Overview
6.2   Impact Analysis
6.3   Market Drivers
6.3.1   Rising Prevalence of Genetic Disorders
6.3.2   Increasing Prevalence of Various Types of Cancer, Globally
6.3.3   Increasing Research Funding in the Field of Genomics
6.4   Market Restrains
6.4.1   Expensive Sequencing Procedures and Their Applications in Medical Treatments
6.4.2   High Capital Requirement Hampering the Expansion of Global Reach
6.4.3   Stringent Regulatory Standards
6.5   Market Opportunities
6.5.1   Technological Advancements for Exome Sequencing
6.5.2   Rise of Direct-to-Consumer (DTC) Testing Services
6.5.3   Massive Scope for Adoption of NGS-Based in Emerging Nations

7.1    Legal and Regulatory Framework
         7.1.1    United States
         7.1.2    Europe
                     7.1.2.1    Germany
                     7.1.2.2    France
                     7.1.2.3    Italy
         7.1.3    Asia-Pacific
                     7.1.3.1    China
                     7.1.3.2    Japan
                     7.1.3.3    Australia
7.2    Reimbursement Scenario

8.1   Overview
8.2   Kits and Consumables
8.3   Services
8.4   Others

9.1   Overview
9.2   Tumor Tissue
9.3   Bone Marrow
9.4   Saliva
9.5   Blood
9.6   Other Sample Types

10.1   Overview
10.2   Next Generation Sequencing (NGS)
10.3   Polymerase Chain Reaction (PCR)
10.4   Immunohistochemistry (IHC)
10.5   In-Situ Hybridization (ISH)
10.6   Microarray Techniques
10.7   Other Technologies

11.1   Overview
11.2   Breast Cancer
11.3   Lung Cancer
11.4   Prostate Cancer
11.5   Colorectal Cancer
11.6   Melanoma
11.7   Other Oncology Hereditary Genetic Testing

12.1   Overview
12.2   Cardiomyopathy
12.3   Aortopathy
12.4   Arrhythmia
12.5   Other Cardiology Hereditary Genetic Testing

13.1   Overview
13.2   Epilepsy
13.3   Neurodegenerative Disorders
13.4   Neuromuscular Disorders
13.5   Other Neurology Hereditary Genetic Testing

14.1   Newborn Screening
14.2   Prenatal Screening (NIPT) and Preimplantation Testing
14.3   Rare Disease Testing
14.4   Direct-to-Consumer Testing

15.1   Academic and Research
15.2   Clinical Diagnostics
15.3   Drug discovery
15.4   Monitoring and Screening

16.1   Overview
16.2   North America
16.2.1   U.S.
16.2.2   Canada
16.3   Europe
16.3.1   Germany
16.3.2   France
16.3.3   Italy
16.3.4   U.K.
16.3.5   Spain
16.3.6   Russia
16.3.7   Netherlands
16.3.8   Rest-of-Europe
16.4   Asia-Pacific
16.4.1   China
16.4.2   Japan
16.4.3   India
16.4.4   Australia
16.4.5   Singapore
16.4.6   Rest-of-APAC
16.5   Latin America
16.5.1   Brazil
16.5.2   Mexico
16.5.3   Rest-of-Latin America
16.6   Rest-of-the-World (RoW)

17.1   Overview
17.2   Agilent Technologies, Inc.
17.2.1   Company Overview
17.2.2   Role of Agilent Technologies, Inc. in the Global Hereditary Genetic Testing Market
17.2.3   Financials
17.2.4   Key Insights About Financial Health of the Company
17.2.5   SWOT Analysis
17.3   Ambry Genetics
17.3.1   Company Overview
17.3.2   Role of Ambry Genetics in the Global Hereditary Genetic Testing Market
17.3.3   SWOT Analysis
17.4   Beijing Genomics Institute (BGI)
17.4.1   Company Overview
17.4.2   Role of BGI in the in the Global Hereditary Genetic Testing Market
17.4.3   SWOT Analysis
17.5   CENTOGENE AG
17.5.1   Company Overview
17.5.2   Role of CENTOGENE AG in the Global Hereditary Genetic Testing Market
17.5.3   SWOT Analysis
17.6   Eurofins Scientific SE
17.6.1   Company Overview
17.6.2   Role of Eurofins Scientific SE in the Global Hereditary Genetic Testing Market
17.6.3   Financials
17.6.4   SWOT Analysis
17.7   F. Hoffmann-La Roche Ltd
17.7.1   Company Overview
17.7.2   Role of F. Hoffmann-La Roche Ltd in the Global Hereditary Genetic Testing Market
17.7.3   Financials
17.7.4   Key Insights About Financial Health of the Company
17.7.5   SWOT Analysis
17.8   Illumina, Inc.
17.8.1   Company Overview
17.8.2   Role of Illumina, Inc. in the Global Hereditary Genetic Testing Market
17.8.3   Financials
17.8.4   Key Insights About Financial Health of the Company
17.8.5   SWOT Analysis
17.9   Laboratory Corporation of America Holdings
17.9.1   Company Overview
17.9.2   Role of Laboratory Corporation of America Holdings in the Global Hereditary Genetic Testing Market
17.9.3   Financials
17.9.4   SWOT Analysis
17.10 Myriad Genetics, Inc.
17.10.1   Company Overview
17.10.2   Role of Myriad Genetics, Inc. in the Global Hereditary Genetic Testing Market
17.10.3   SWOT Analysis
17.11  PerkinElmer, Inc.
17.11.1   Company Overview
17.11.2   Role of PerkinElmer Inc, in Global Hereditary Genetic Testing Market
17.11.3   Financials
17.11.4   Key Insights About Financial Health of the Company
17.11.5   SWOT Analysis
17.12  Quest Diagnostics Incorporated
17.12.1   Company Overview
17.12.2   Role of Quest Diagnostics Incorporated in the Global Hereditary Genetic Testing Market
17.12.3   Financials
17.12.4   SWOT Analysis
17.13  Thermo Fisher Scientific Inc.
17.13.1   Company Overview
17.13.2   Role of Thermo Fisher Scientific Inc. in the Global Hereditary Genetic Testing Market
17.13.3   Financials
17.13.4   Key Insights About Financial Health of the Company
17.13.5   SWOT Analysis
17.14  Emerging Companies
17.14.1   COLOR
17.14.1.1   Company Overview
17.14.2   Natera, Inc.
17.14.2.1   Company Overview

Table 7.1:   Regulatory Bodies Governing Hereditary Genetic Testing
Table 8.1:   Key Products and Application in Global Hereditary Genetic Testing Market
Table 11.1:   Available Hereditary Genetic Tests for Breast Cancer
Table 11.2:   Available Hereditary Genetic Tests for Lung Cancer
Table 11.3:   Available Hereditary Genetic Tests for Lung Cancer
Table 11.4:   Available Hereditary Genetic Tests for Colorectal Cancer
Table 11.5:   Available Hereditary Genetic Tests for Melanoma
Table 11.6:   Available Hereditary Genetic Tests for Others
Table 12.1:   Available Hereditary Genetic Tests for Cardiomyopathy
Table 12.2:   Available Hereditary Genetic Tests for Aortopathy
Table 12.3:   Available Hereditary Genetic Tests for Arrhythmia
Table 12.4:   Available Hereditary Genetic Tests for Others
Table 13.1:   Available Hereditary Genetic Tests for Epilepsy
Table 13.2:   Available Hereditary Genetic Tests for Neurodegenerative Disorders
Table 13.3:   Available Hereditary Genetic Tests for Neuromuscular Disorders
Table 13.4:   Available Hereditary Genetic Tests for Others
Table 17.1:   BIS Insight
Table 17.2:   BIS Insight

Figure 1:   Launched Hereditary Genetic Test Units (2017)
Figure 2:   Impact of Market Drivers and Market Restraints on the Global Hereditary Genetic Testing Market
Figure 3:   Global Hereditary Genetic Testing Market (by Product), $Billion, 2019 vs. 2030
Figure 4:   Global Hereditary Genetic Testing Market (by Application Area), $Billion, 2019 vs. 2030
Figure 5:   Global Hereditary Genetic Testing Market Snapshot, $Billion, 2019 and 2030
Figure 2.1:   Global Hereditary Genetic Testing Market Segmentation
Figure 3.1:   Global Hereditary Genetic Testing Market Methodology
Figure 3.2:   Primary Research Methodology
Figure 3.3:   Bottom-Up Approach (Segment-Wise Analysis)
Figure 4.1:   Share of Key Developments and Strategies, January 2017–April 2020
Figure 4.2:   Number of Product Launches (by Company), January 2017–April 2020
Figure 4.3:   Synergistic Activities Share (by Company), January 2017–April 2020
Figure 4.4:   Business Expansion Activities Share (by Company), January 2017-April 2020
Figure 4.5:   Market Share Analysis for the Global Hereditary Genetic Testing Market, 2019
Figure 4.6:   Growth Share Matrix for Global Hereditary Genetic Testing Market (by Company), 2018-2019
Figure 6.1:   Impact Analysis
Figure 6.2:   People Suffering from CF (Cystic Fibrosis), 2002-2017:
Figure 6.3:   Number of Deaths (in Millions) by Different Forms of Cancer, 2018
Figure 7.1:   Overall Reimbursement Scenario: 2018
Figure 8.1:   Global Hereditary Genetic Testing Market (by Product)
Figure 8.2:   Global Hereditary Genetic Testing Market (Kits), 2019-2030
Figure 8.3:   Global Hereditary Genetic Testing Market (Consumables), 2019-2030
Figure 8.4:   Global Hereditary Genetic Testing Market (Services), 2019-2030
Figure 8.5:   Global Hereditary Genetic Testing Market (Others), 2019-2030
Figure 9.1:   Global Hereditary Genetic Testing Market (by Sample Type)
Figure 9.2:   Global Hereditary Genetic Testing Market (Tumor Tissue), 2019-2030
Figure 9.3:   Global Hereditary Genetic Testing Market (Bone Marrow), 2019-2030
Figure 9.4:   Global Hereditary Genetic Testing Market (Saliva), 2019-2030
Figure 9.5:   Global Hereditary Genetic Testing Market (Blood), 2019-2030
Figure 9.6:   Global Hereditary Genetic Testing Market (Other Sample Types), 2019-2030
Figure 10.1:   Global Hereditary Genetic Testing Market (by Technology)
Figure 10.2:   Global Hereditary Genetic Testing Market (Next Generation Sequencing), 2019-2030
Figure 10.3:   Global Hereditary Genetic Testing Market (Polymerase Chain Reaction), 2019-2030
Figure 10.4:   Global Hereditary Genetic Testing Market (Immunohistochemistry), 2019-2030
Figure 10.5:   Global Hereditary Genetic Testing Market (In-Situ Hybridization), 2019-2030
Figure 10.6:   Global Hereditary Genetic Testing Market (Microarray Techniques), 2019-2030
Figure 10.7:   Global Hereditary Genetic Testing Market (Other Technologies), 2019-2030
Figure 11.1:   Global Hereditary Genetic Testing Market (Oncology Genetic Testing Type), 2019-2030
Figure 11.2:   Global Hereditary Genetic Testing Market (Breast Cancer), 2019-2030
Figure 11.3:   Global Hereditary Genetic Testing Market (Lung Cancer), 2019-2030
Figure 11.4:   Global Hereditary Genetic Testing Market (Prostate Cancer), 2019-2030
Figure 11.5:   Global Hereditary Genetic Testing Market (Colorectal Cancer), 2019-2030
Figure 11.6:   Global Hereditary Genetic Testing Market (Melanoma), 2019-2030
Figure 11.7:   Global Hereditary Genetic Testing Market (Other Oncology Hereditary Genetic Testing), 2019-2030
Figure 12.1:   Global Hereditary Genetic Testing Market (Cardiology Genetic Testing Type), 2019-2030
Figure 12.2:   Global Hereditary Genetic Testing Market (Cardiomyopathy), 2019-2030
Figure 12.3:   Global Hereditary Genetic Testing Market (Aortopathy), 2019-2030
Figure 12.4:   Global Hereditary Genetic Testing Market (Arrhythmia), 2019-2030
Figure 12.5:   Global Hereditary Genetic Testing Market (Other Cardiology Hereditary Genetic Testing), 2019-2030
Figure 13.1:   Global Hereditary Genetic Testing Market (Neurology Genetic Testing Type), 2019-2030
Figure 13.2:   Global Hereditary Genetic Testing Market (Epilepsy), 2019-2030
Figure 13.3:   Global Hereditary Genetic Testing Market (Neurodegenerative Disorders), 2019-2030
Figure 13.4:   Global Hereditary Genetic Testing Market (Neuromuscular Disorders), 2019-2030
Figure 13.5:   Global Hereditary Genetic Testing Market (Other Neurology Hereditary Genetic Testing), 2019-2030
Figure 14.1:   Figure xx: Global Hereditary Genetic Testing Market (Newborn Screening), 2019-2030
Figure 14.2:   Global Hereditary Genetic Testing Market (Prenatal Screening and Preimplantation Testing), 2019-2030
Figure 14.3:   Global Hereditary Genetic Testing Market (Rare Disease Testing), 2019-2030
Figure 14.4:   Global Hereditary Genetic Testing Market (Direct-to-Consumer Testing), 2019-2030
Figure 15.1:   Global Hereditary Genetic Testing Market (Academic and Research), 2019-2030
Figure 15.2:   Global Hereditary Genetic Testing Market (Clinical Diagnostics), 2019-2030
Figure 15.3:   Global Hereditary Genetic Testing Market (Drug Discovery), 2019-2030
Figure 15.4:   Global Hereditary Genetic Testing Market (Monitoring and Screening), 2019-2030
Figure 16.1:   Global Hereditary Genetic Testing Market (by Region), 2019 and 2030
Figure 16.2:   Global Hereditary Genetic TestingMarket (by Region), 2019-2030
Figure 16.3:   Global Hereditary Genetic Testing Market Share (by Region), 2019
Figure 16.4:   Global Hereditary Genetic Testing Market Share (by Region), 2030
Figure 16.5:   North America Hereditary Genetic Testing Market, 2019-2030
Figure 16.6:   North America: Market Dynamics
Figure 16.7:   North America Hereditary Genetic Testing Market (by Testing Type), 2019-2030
Figure 16.8:   North America Hereditary Genetic Testing Market (by Country), 2019-2030
Figure 16.9:   U.S. Hereditary Genetic TestingMarket, 2019-2030
Figure 16.10:   Canada Hereditary Genetic Testing Market, 2019-2030
Figure 16.11:   Europe Hereditary Genetic Testing Market, 2019-2030
Figure 16.12:   Europe: Market Dynamics
Figure 16.13:   Europe Hereditary Genetic Testing Market (by Testing Type), 2019-2030
Figure 16.14:   Europe Hereditary Genetic Testing Market (by Country), 2019-2030
Figure 16.15:   Germany Hereditary Genetic Testing Market, 2019-2030
Figure 16.16:   France Hereditary Genetic testing Market, 2019-2030
Figure 16.17:   Italy Hereditary Genetic Testing Market, 2019-2030
Figure 16.18:   U.K. Hereditary Genetic Testing Market, 2019-2030
Figure 16.19:   Spain Hereditary Genetic Testing Market, 2019-2030
Figure 16.20:   Russia Hereditary Genetic Testing Market, 2019-2030
Figure 16.21:   Netherlands Hereditary Genetic Testing Market, 2019-2030
Figure 16.22:   Rest-of-Europe Hereditary Genetic Testing Market, 2019-2030
Figure 16.23:   Asia-Pacific Hereditary Genetic Testing Market, 2019-2030
Figure 16.24:   APAC: Market Dynamics
Figure 16.25:   Asia-Pacific Hereditary Genetic Testing Market (by Testing Type), 2019-2030
Figure 16.26:   APAC Hereditary Genetic Testing Market (by Country), 2019-2030
Figure 16.27:   China Hereditary Genetic Testing Market, 2019-2030
Figure 16.28:   Japan Hereditary Genetic Testing Market, 2019-2030
Figure 16.29:   India Hereditary Genetic Testing Market, 2019-2030
Figure 16.30:   Australia Hereditary Genetic TestingMarket, 2019-2030
Figure 16.31:   Singapore Hereditary Genetic Testing Market, 2019-2030
Figure 16.32:   RoAPAC Hereditary Genetic Testing Market, 2019-2030
Figure 16.33:   Latin America Hereditary Genetic Testing Market, 2019-2030
Figure 16.34:   Latin America: Market Dynamics
Figure 16.35:   Latin America Hereditary Genetic Testing Market (by Testing Type), 2019-2030
Figure 16.36:   Latin America Hereditary Genetic Testing Market (by Country), 2019-2030
Figure 16.37:   Brazil Hereditary Genetic Testing Market, 2019-2030
Figure 16.38:   Mexico Hereditary Genetic Testing Market, 2019-2030
Figure 16.39:   Rest-of-Latin America Hereditary Genetic Testing Market, 2019-2030
Figure 16.40:   RoW Hereditary Genetic Testing Market, 2019-2030
Figure 16.41:   Rest-of-the-World (RoW) Hereditary Genetic Testing Market (by Testing Type), 2019-2030
Figure 17.1:   Total Number of Companies Profiled
Figure 17.2:   Agilent Technologies, Inc.: Product Portfolio
Figure 17.3:   Agilent Technologies, Inc.: Overall Financials, 2017-2019
Figure 17.4:   Agilent Technologies, Inc.: Revenue (by Segment), 2017-2019
Figure 17.5:   Agilent Technologies, Inc.: Revenue (by Region), 2016-2018
Figure 17.6:   Agilent Technologies, Inc.: R&D Expenditure, 2017-2019
Figure 17.7:   Agilent Technologies, Inc.: SWOT Analysis
Figure 17.8:   Ambry Genetics: Product Portfolio
Figure 17.9:   Ambry Genetics: SWOT Analysis
Figure 17.10:   BGI: Product Portfolio
Figure 17.11:   BGI: SWOT Analysis
Figure 17.12:   CENTOGENE AG: Overall Product Portfolio
Figure 17.13:   CENTOGENE AG: SWOT Analysis
Figure 17.14:   Eurofins Scientific SE: Overall Financials, 2016-2018
Figure 17.15:   Eurofins Scientific SE: Revenue (by Region), 2016-2018
Figure 17.16:   Eurofins Scientific SE.: SWOT Analysis
Figure 17.17:   F. Hoffmann-La Roche Ltd:Product Portfolio
Figure 17.18:   F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 17.19:   F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
Figure 17.20:   F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
Figure 17.21:   F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
Figure 17.22:   F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 17.23:   Illumina, Inc.: Product Portfolio
Figure 17.24:   Illumina, Inc.: Overall Financials, 2017-2019
Figure 17.25:   Illumina, Inc.: Revenue (by Segment), 2017-2019
Figure 17.26:   Illumina, Inc.: R&D Expenditure, 2017-2019
Figure 17.27:   Illumina, Inc.: SWOT Analysis
Figure 17.28:   Laboratory Corporation of America Holdings: Overall Financials, 2017-2019
Figure 17.29:   Laboratory Corporation of America Holdings: Revenue (by Segment), 2017-2019
Figure 17.30:   Laboratory Corporation of America Holdings: Revenue (by Region), 2019
Figure 17.31:   Laboratory Corporation of America Holdings: SWOT Analysis
Figure 17.32:   Myriad Genetics, Inc.: Product Portfolio
Figure 17.33:   Myriad Genetics, Inc.: SWOT Analysis
Figure 17.34:   PerkinElmer, Inc.: Overall Financials, 2017-2019
Figure 17.35:   PerkinElmer, Inc.: Revenue (by Segment), 2017-2019
Figure 17.36:   PerkinElmer, Inc.: Revenue (by Region), 2018-2019
Figure 17.37:   PerkinElmer, Inc.: R&D Expenditure,2017-2019
Figure 17.38:   PerkinElmer, Inc.: SWOT Analysis
Figure 17.39:   Product Portfolio: Quest Diagnostics Incorporated
Figure 17.40:   Quest Diagnostics Incorporated: Overall Financials, 2017-2019
Figure 17.41:   Quest Diagnostics Incorporated: SWOT Analysis
Figure 17.42:   Thermo Fisher Scientific Inc.: Product Portfolio
Figure 17.43:   Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019
Figure 17.44:   Thermo Fisher Scientific Inc.: Revenue (by Segment), 2017-2019
Figure 17.45:   Thermo Fisher Scientific Inc.: Revenue (by Region), 2017-2019
Figure 17.46:   Thermo Fisher Scientific Inc.: R&D Expenditure, 2017-2019
Figure 17.47:   Thermo Fisher Scientific Inc.: SWOT Analysis

Empty